From Self-sufficiency
Jump to: navigation, search
Systematic (IUPAC) name
ATC code A04AD13 (WHO)
PubChem CID 23725089
Chemical data
Formula C30H35F7N4O2
Molar mass 616.26 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Casopitant (trade names Rezonic (US), Zunrisa (EU)) is an neurokinin 1 (NK1) receptor antagonist undergoing research for the treatment of chemotherapy-induced nausea and vomiting (CINV).[1] It is currently under development by GlaxoSmithKline (GSK).

In July 2008, the company filed a marketing authorisation application with the European Medicines Agency. The application was withdrawn in September 2009 because GSK decided that further safety assessment was necessary.[2]

See also


Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

  1. Lohr L (2008). "Chemotherapy-induced nausea and vomiting". Cancer J. 14 (2): 85–93. doi:10.1097/PPO.0b013e31816a0f07. PMID 18391612. 
  2. "GlaxoSmithKline withdraws its marketing authorisation application for Zunrisa" (PDF). London: EMEA. 13 October 2009. Retrieved 21 December 2009.